Affordable Access

Access to the full text

The effects of vitamin E supplementation on malondialdehyde as a biomarker of oxidative stress in haemodialysis patients: a systematic review and meta-analysis

Authors
  • Bergin, Peter1
  • Leggett, Aoife1
  • Cardwell, Chris R.1
  • Woodside, Jayne V.1
  • Thakkinstian, Ammarin2
  • Maxwell, Alexander P.1
  • McKay, Gareth J.1, 3
  • 1 Queen’s University Belfast, Belfast, UK , Belfast (United Kingdom)
  • 2 Mahidol University, Bangkok, Thailand , Bangkok (Thailand)
  • 3 Centre for Public Health, Queen’s University Belfast, Royal Victoria Hospital, Belfast, BT12 6BA, UK , Belfast (United Kingdom)
Type
Published Article
Journal
BMC Nephrology
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Apr 09, 2021
Volume
22
Issue
1
Identifiers
DOI: 10.1186/s12882-021-02328-8
Source
Springer Nature
Keywords
License
Green

Abstract

BackgroundHaemodialysis (HD) patients tend to have higher levels of oxidative stress (OS), associated with increased morbidity and premature mortality, compared to the general population. Levels of malondialdehyde (MDA), a biomarker of OS, are reduced by the antioxidant properties of vitamin E (VE) but outcomes from randomised control trials of VE supplementation on MDA in HD patients have been inconsistent.MethodsWe undertook a systematic review and meta-analysis of adult HD patients from VE supplementation studies with measures of MDA. The following search criteria of MEDLINE and EMBASE were considered from inception to January 2020: ‘dialysis’ AND ‘Vitamin E OR tocopherol’ AND ‘malondialdehyde OR MDA’. Two reviewers independently extracted study data and assessed risk of bias. Mean MDA levels and standard deviation were determined before and after VE supplementation. Standardised mean difference (SMD) and standard error were calculated as the within person difference and units of measure were not consistently recorded across all studies. The SMD were pooled using random effects meta-analysis.ResultsThe SMD of MDA levels from 18 comparisons was significantly lower in HD patients following VE supplementation (− 1.55; confidence interval: − 2.17 to − 0.94, P < 0.00001). There were significant levels of heterogeneity between studies (I2 value = 91%; P < 0.00001) with evidence of potential publication bias toward smaller studies.ConclusionsOur findings support the use of VE to reduce the effects of OS in HD patients although high levels of heterogeneity and variation in the methodological approaches used by some studies highlight the need for further investigation.

Report this publication

Statistics

Seen <100 times